Franklin Resources Inc Ironwood Pharmaceuticals Inc Transaction History

Franklin Resources Inc

$313 Billion
Q2 2024

A detailed history of Franklin Resources Inc transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Franklin Resources Inc holds 320,175 shares of IRWD stock, worth $1.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

320,175

Previous 311,340 2.84%

Holding current value

$1.44 Million

Previous $2.71 Million 23.02%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.58 - $8.61 $49,299 - $76,069	8,835 Added 2.84%	320,175 $2.09 Million
Q1 2024 May 13, 2024	BUY	$8.32 - $15.45 $2.35 Million - $4.37 Million	282,762 Added 989.44%	311,340 $2.71 Million
Q4 2023 Feb 09, 2024	BUY	$8.79 - $11.51 $77,545 - $101,541	8,822 Added 44.65%	28,578 $326,000
Q3 2023 Nov 13, 2023	SELL	$8.25 - $11.35 $27,893 - $38,374	-3,381 Reduced 14.61%	19,756 $190,000
Q2 2023 Aug 11, 2023	BUY	$10.1 - $11.6 $3,262 - $3,746	323 Added 1.42%	23,137 $246,000
Q1 2023 May 12, 2023	BUY	$10.37 - $12.56 $29,015 - $35,142	2,798 Added 13.98%	22,814 $240,000
Q4 2022 Feb 10, 2023	SELL	$9.9 - $12.43 $2,880 - $3,617	-291 Reduced 1.43%	20,016 $247,000
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $62,087 - $75,802	6,123 Added 43.17%	20,307 $211,000
Q2 2022 Aug 11, 2022	BUY	$11.05 - $12.72 $23,790 - $27,386	2,153 Added 17.9%	14,184 $163,000
Q1 2022 May 13, 2022	BUY	$10.61 - $12.88 $20,509 - $24,897	1,933 Added 19.14%	12,031 $151,000
Q4 2021 Feb 11, 2022	BUY	$10.86 - $13.95 $109,664 - $140,867	10,098 New	10,098 $117,000

Others Institutions Holding IRWD

# of Institutions

247

Shares Held

171M

Call Options Held

11.2M

Put Options Held

28.5K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $691M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account

Franklin Resources Inc Ironwood Pharmaceuticals Inc Transaction History